Alpha 2.0
Login Register
» Articles » PMID: 27358710

Successfully Treated Acute Fulminant Myocarditis Induced by Ulcerative Colitis with Extracorporeal Life Support and Infliximab

Overview
Journal J Cardiovasc Ultrasound
Specialty Cardiology & Vascular Diseases
Date 2016 Jul 1
PMID 27358710
Citations 6
Authors
Han-Kyul Kim
Kun Il Kim
Sung Won Jung
Hee-Sun Mun
Jung Rae Cho
Namho Lee
Min-Kyung Kang
Affiliations
Soon will be listed here.
Abstract

We report a case of successfully treated acute fulminant myocarditis induced by ulcerative colitis with extracorporeal life support and infliximab. Myocarditis is a rare but crucial complication during an exacerbation of inflammatory bowel disease. In our case, we applied extracorporeal membrane oxygenation (ECMO) for cardiac rest under impression of acute myocarditis associated with ulcerative colitis, and added infliximab for uncontrolled inflammation by corticosteroid. As a result, our patient was completely recovered with successful weaning of ECMO.

Citing Articles

Mesalazine-Induced Myocarditis in Inflammatory Bowel Disease: A Systematic Review.

Jhakri K, Al-Shudifat M, Sumra B, Kocherry C, Shamim H, Mohammed L Cureus. 2025; 17(1):e78208.

PMID: 40027008 PMC: 11872002. DOI: 10.7759/cureus.78208.

Mesalazine-induced myocarditis in a patient with ulcerative colitis: a case report.

Littlewood S, Nikolou E, Aziz W, Anderson L Eur Heart J Case Rep. 2024; 8(9):ytae458.

PMID: 39279885 PMC: 11395831. DOI: 10.1093/ehjcr/ytae458.

Myocarditis as an extraintestinal manifestation of ulcerative colitis: A case report and review of the literature.

Wang Y, Shi W, Wang J, Li Y, Tian Z, Jiao Y World J Clin Cases. 2022; 10(27):9750-9759.

PMID: 36186201 PMC: 9516903. DOI: 10.12998/wjcc.v10.i27.9750.

A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease.

Cesa K, Cunningham C, Harris T, Sunseri W Cureus. 2022; 14(6):e26366.

PMID: 35911289 PMC: 9334219. DOI: 10.7759/cureus.26366.

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges.

Huertas R, Saavedra Serrano C, Perna C, Ferrer Gomez A, Alonso Gordoa T Cancer Manag Res. 2019; 11:4541-4548.

PMID: 31191015 PMC: 6529611. DOI: 10.2147/CMAR.S185202.

References
1.
Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y . C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol. 2015; 15:103. PMC: 4535387. DOI: 10.1186/s12876-015-0333-z. View
2.
Becker S, Wishnitzer R, Botwin S, Eliraz A, Bass D . Myopericarditis associated with inflammatory bowel disease. J Clin Gastroenterol. 1981; 3(3):267-70. DOI: 10.1097/00004836-198109000-00011. View
3.
Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A . Update on myocarditis. J Am Coll Cardiol. 2012; 59(9):779-92. DOI: 10.1016/j.jacc.2011.09.074. View
4.
Varnavas V, Reinsch N, Perrey M, Nensa F, Schlosser T, Baba H . Recurrent lymphocytic myocarditis in a young male with ulcerative colitis. Eur J Med Res. 2014; 19:11. PMC: 3942255. DOI: 10.1186/2047-783X-19-11. View
5.
Gruenhagen B, Alraies M, Vakil K, March S . Ulcerative colitis-induced myocarditis. BMJ Case Rep. 2014; 2014. PMC: 4039753. DOI: 10.1136/bcr-2014-204818. View